Versartis presents positive preclinical data on 2 product candidates at ENDO 09
Wednesday, June 10, 2009 - 13:49
in Health & Medicine
Washington, DC -- June 10, 2009 -- Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, today presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (IL-1ra-rPEG) for treatment of type 1 and type 2 diabetes, at the Endocrine Society's Annual M